1. Phylogeny  
   LIM domain kinase 1 (LIMK1; UniProt ID: P53667) is a serine/threonine‐protein kinase that is highly conserved across metazoans and occupies a defined position within the human kinome. It is classified within the STE group – sometimes also referred to within the broader context as part of the tyrosine kinase‐like (TKL) family – and forms a distinct subfamily together with its paralog LIMK2. LIMK1 orthologs have been identified in a diverse array of species ranging from invertebrates to mammals, which underscores its pivotal role in governing cytoskeletal dynamics and cellular morphology. Phylogenetic analyses based on the conserved kinase catalytic domain sequences consistently place LIMK1 among kinases that are involved in the regulation of actin dynamics, particularly those that function downstream of Rho family GTPase signaling pathways. Comparative studies indicate that the evolutionary history of the LIM kinase family is marked by gene duplication events that generated distinct yet partly overlapping isoforms with tissue- and context-specific roles. (anderson2023howmanykinases pages 1-2, anderson2023howmanykinases pages 30-31, chatterjee2022structuralaspectsof pages 1-3)
2. Reaction Catalyzed  
   LIMK1 functions by catalyzing the transfer of the γ-phosphate from ATP to specific hydroxyl groups of serine and threonine residues present in its substrate target proteins. In biochemical terms, the reaction can be expressed as:  
     ATP + [protein]–(L‑serine or L‑threonine) → ADP + [protein]–(phospho‑L‑serine/threonine) + H⁺.  
   This fundamental phosphorylation event is essential to the regulation of the activity of key actin-depolymerizing factors and other downstream effectors. (anderson2023howmanykinases pages 1-2, anderson2023howmanykinases pages 27-28)
3. Cofactor Requirements  
   The catalytic activity of LIMK1 is dependent upon the presence of divalent metal ions. In particular, Mg²⁺ is required as an essential cofactor. This metal ion coordinates the binding of ATP within the active site of the enzyme, thus facilitating the transfer of the phosphate group during catalysis. (anderson2023howmanykinases pages 1-2)
4. Substrate Specificity  
   LIMK1 exhibits a substrate specificity profile that is characteristic of serine/threonine kinases involved in the regulation of the actin cytoskeleton. The enzyme specifically targets serine and threonine residues located within regulatory sequences of actin-modulating proteins. Its well-characterized physiological substrates include the actin depolymerizing factors cofilin‑1 (CFL1), cofilin‑2 (CFL2), and destrin (DSTN). Phosphorylation of these substrates, particularly at critical sites such as serine‑3 on cofilin, leads to their inactivation and results in stabilization of filamentous actin (F‑actin). In addition, LIMK1 phosphorylates tubulin polymerization-promoting protein (TPPP) on serine residues, a modification that promotes microtubule disassembly. Although a precise consensus phosphorylation motif for LIMK1 has not been as rigorously defined as for some other kinases, substrate profiling studies – including those derived from the atlas of substrate specificities covering the human serine/threonine kinome – suggest that LIMK1 preferentially phosphorylates its actin-regulatory substrates within a local sequence context that favors effective substrate docking and recognition. (bello2020developingandapplying pages 13-16, ribba2022theroleof pages 12-13, johnson2023anatlasof pages 1-2, salah2019lessonsfromlimk1 pages 12-13)
5. Structure  
   The structural organization of LIMK1 is highly modular and consists of several distinct domains that contribute to both catalytic and regulatory functions. At its extreme N-terminus, LIMK1 contains two LIM domains, which are zinc finger motifs that mediate protein–protein interactions and play an important role in directing subcellular localization as well as in assembling multiprotein complexes. Immediately downstream of the LIM domains lies a centrally positioned PDZ domain, which also contributes to protein binding and may function in organizing signaling complexes by interacting with short C-terminal sequences of partner proteins. The C-terminal portion of LIMK1 is dominated by the kinase catalytic domain, which adopts the classical bi-lobed structure observed in most eukaryotic protein kinases. The smaller N-lobe, rich in β-sheets, and the larger C-lobe, predominantly composed of α-helices, together form a catalytic cleft that binds ATP. Within the kinase domain, several conserved motifs have been identified: the Gly-rich loop, crucial for ATP binding; the VAIK motif, which typically contains a lysine residue that interacts with ATP; the HRD catalytic loop, which is essential for phosphotransfer, and the DFG motif that coordinates the binding of Mg²⁺ and ATP. A key regulatory element in this domain is the activation loop, which houses a conserved threonine residue that must be phosphorylated by upstream kinases in order to transition LIMK1 into its active conformation. Structural models, including those derived from crystallographic studies and AlphaFold predictions, reveal that activation loop phosphorylation induces a conformational change – aligning regulatory features such as the hydrophobic spine and repositioning the C-helix – to create an active catalytic site. (chatterjee2022structuralaspectsof pages 1-3, chatterjee2022structuralaspectsof pages 3-4, chatterjee2022structuralaspectsof pages 4-6, chatterjee2022structuralaspectsof pages 8-10, chatterjee2022structuralaspectsof pages 10-11, mittelstaedt2012structuralandfunctional pages 23-32)
6. Regulation  
   Regulation of LIMK1 activity is principally mediated by phosphorylation events that occur within its activation loop. Upstream kinases such as ROCK1, PAK1, and PAK4 phosphorylate a conserved threonine residue within the activation loop of LIMK1 – a modification that is essential for achieving full catalytic activity. This phosphorylation event acts as a molecular switch that induces conformational rearrangements within the kinase domain, aligning key structural elements such as the activation loop and the C-helix to facilitate substrate binding and phosphotransfer. In addition to phosphorylation-driven activation, the LIM and PDZ domains present in the N-terminal region of the protein are thought to contribute to the regulation of LIMK1 by mediating intramolecular interactions and influencing subcellular localization, thereby controlling substrate accessibility. Although precise details of allosteric regulation via these domains remain under investigation, current evidence supports a model in which both covalent modification and protein-protein interactions synergistically modulate LIMK1 activity. (anderson2023howmanykinases pages 1-2, bello2020developingandapplying pages 13-16, salah2019lessonsfromlimk1 pages 13-13, chatterjee2022structuralaspectsof pages 11-12)
7. Function  
   LIMK1 is critically important in the regulation of actin cytoskeleton dynamics. Its primary biological role is to phosphorylate and inactivate actin depolymerizing factors, most notably cofilin‑1, cofilin‑2, and destrin. By phosphorylating these substrates, LIMK1 prevents the severing of filamentous actin (F‑actin), thereby contributing to the stabilization of actin filaments and the maintenance of cellular architecture. Functionally, LIMK1 operates downstream of Rho family GTPase signaling pathways, integrating signaling cues transmitted through upstream effectors such as ROCK1 and PAK kinases to modulate processes as diverse as cell motility, cell cycle progression, and cellular differentiation. In addition to its effects on actin dynamics, LIMK1 phosphorylates tubulin polymerization-promoting protein (TPPP), which promotes microtubule disassembly and thereby contributes to the cross-talk between the actin and microtubule networks. LIMK1 is also implicated in neuronal functions; its role in stimulating axonal outgrowth supports its involvement in brain development and synaptic plasticity. Expression patterns indicate that LIMK1 is predominantly expressed in neural tissues, although it is also present in other tissues where dynamic remodeling of the cytoskeleton is required. (anderson2023howmanykinases pages 1-2, salah2019lessonsfromlimk1 pages 12-13, ribba2022theroleof pages 12-13, bello2020developingandapplying pages 82-87)
8. Other Comments  
   Given its central role in regulating cytoskeletal dynamics through the modulation of actin-depolymerizing proteins, LIMK1 has emerged as a potential therapeutic target for diseases characterized by dysregulated cell motility and aberrant cytoskeletal organization. Altered LIMK1 expression and activity have been linked to cancer metastasis, where enhanced stabilization of the actin cytoskeleton may contribute to invasive behavior, as well as to various neurological disorders such as fragile X syndrome and amyotrophic lateral sclerosis. Ongoing research has led to the development of several experimental inhibitors of LIMK1, including covalent inhibitors that exploit unique cysteine residues within its kinase domain. Despite promising preclinical data, no LIMK1-specific inhibitor has yet achieved clinical approval. The continuing effort to design highly selective small-molecule probes against LIMK1 is driven both by its potential as a drug target and by the need for chemical tools to dissect its contributions to cell signaling pathways. (villalonga2023limkinaseslimk1 pages 1-2, salah2019lessonsfromlimk1 pages 12-13, mandel2025covalenttargetingleads pages 12-16, southekal2021integrativeanalysisof pages 114-120, mandel2025repurposingofthe pages 11-12)
9. References  
   Anderson, B. et al. How many kinases are druggable? a review of our current understanding. Biochemical Journal, 480:1331-1363, Aug 2023. (anderson2023howmanykinases pages 1-2, anderson2023howmanykinases pages 27-28)  
   Bello, T. Developing and applying systems‐based approaches to kinase‐centered biology. (bello2020developingandapplying pages 13-16, bello2020developingandapplying pages 82-87)  
   Chatterjee, D. et al. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. (chatterjee2022structuralaspectsof pages 1-3, chatterjee2022structuralaspectsof pages 3-4, chatterjee2022structuralaspectsof pages 4-6, chatterjee2022structuralaspectsof pages 8-10, chatterjee2022structuralaspectsof pages 10-11, chatterjee2022structuralaspectsof pages 11-12)  
   Fraboulet, T. The role of lim kinases during development: a lens to get a glimpse of their implication in pathologies. Cells, 11:403, Jan 2022. (ribba2022theroleof pages 12-13)  
   Hanke, T. et al. Development and characterization of type i, type ii, and type iii lim‐kinase chemical probes. Journal of Medicinal Chemistry, 65:13264-13287, Sep 2022. (hanke2022developmentandcharacterization pages 1-3, hanke2022developmentandcharacterization pages 30-31)  
   Johnson, J. L. et al. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613(7945), 759-766, Jan 2023. (johnson2023anatlasof pages 1-2, johnson2023anatlasof pages 3-4, johnson2023anatlasof pages 4-5, johnson2023anatlasof pages 7-7, johnson2023anatlasof pages 9-10)  
   Kınalı, M. Leveraging the human kinome for anticancer agent cytotoxicity potency prediction. (kınalı2019leveragingthehuman pages 14-18)  
   Li, G. et al. Design, optimization, and ADMET evaluation of S11A-0000168202: a promising LIMK1 inhibitor for gastric cancer treatment. PLOS One, 20:e0323699, May 2025. (li2025designoptimizationand pages 17-19)  
   Mandel, S. et al. Covalent targeting leads to the development of limk1 isoform-selective inhibitors. BioRxiv, Apr 2025. (mandel2025covalenttargetingleads pages 12-16, mandel2025covalenttargetingleads pages 59-63, mandel2025covalenttargetingleads pages 63-66)  
   Mandel, S. et al. Repurposing of the ripk1-selective benzo[1,4]oxazepin-4-one scaffold for the development of a type iii limk1/2 inhibitor. ACS Chemical Biology, Apr 2025. (mandel2025repurposingofthe pages 11-12)  
   Miller, C. J. & Turk, B. E. Homing in: mechanisms of substrate targeting by protein kinases. Trends in Biochemical Sciences, 43(5), 380-394, May 2018. (miller2018hominginmechanisms pages 18-22)  
   Mittelstaedt, K. Structural and functional characterisation of lim kinases. (mittelstaedt2012structuralandfunctional pages 23-32, mittelstaedt2012structuralandfunctional pages 38-46)  
   Pei, J. & Cong, Q. Computational analysis of regulatory regions in human protein kinases. Protein Science, Sep 2023. (pei2023computationalanalysisof pages 1-2)  
   Reys, V. In silico profiling of protein-kinases inhibitors and study of protein-protein interactions. (reys2022insilicoprofiling pages 32-35)  
   Ribba, S. et al. The role of lim kinases during development: a lens to get a glimpse of their implication in pathologies. Cells, 11:403, Jan 2022. (ribba2022theroleof pages 12-13)  
   Salah, E. et al. Lessons from limk1 enzymology and their impact on inhibitor design. Biochemical Journal, 476:3197-3209, Nov 2019. (salah2019lessonsfromlimk1 pages 12-13, salah2019lessonsfromlimk1 pages 13-13)

References

1. (anderson2023howmanykinases pages 1-2): Brian Anderson, Peter Rosston, Han Wee Ong, Mohammad Anwar Hossain, Zachary W. Davis-Gilbert, and David H. Drewry. How many kinases are druggable? a review of our current understanding. Biochemical Journal, 480:1331-1363, Aug 2023. URL: https://doi.org/10.1042/bcj20220217, doi:10.1042/bcj20220217. This article has 28 citations and is from a domain leading peer-reviewed journal.
2. (anderson2023howmanykinases pages 30-31): Brian Anderson, Peter Rosston, Han Wee Ong, Mohammad Anwar Hossain, Zachary W. Davis-Gilbert, and David H. Drewry. How many kinases are druggable? a review of our current understanding. Biochemical Journal, 480:1331-1363, Aug 2023. URL: https://doi.org/10.1042/bcj20220217, doi:10.1042/bcj20220217. This article has 28 citations and is from a domain leading peer-reviewed journal.
3. (bello2020developingandapplying pages 13-16): T Bello. Developing and applying systems-based approaches to kinase-centered biology. Unknown journal, 2020.
4. (bello2020developingandapplying pages 82-87): T Bello. Developing and applying systems-based approaches to kinase-centered biology. Unknown journal, 2020.
5. (chatterjee2022structuralaspectsof pages 1-3): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
6. (chatterjee2022structuralaspectsof pages 10-11): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
7. (chatterjee2022structuralaspectsof pages 11-12): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
8. (chatterjee2022structuralaspectsof pages 3-4): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
9. (chatterjee2022structuralaspectsof pages 4-6): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
10. (chatterjee2022structuralaspectsof pages 8-10): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
11. (hanke2022developmentandcharacterization pages 1-3): Thomas Hanke, Sebastian Mathea, Julia Woortman, Eidarus Salah, Benedict-Tilman Berger, Anthony Tumber, Risa Kashima, Akiko Hata, Bernhard Kuster, Susanne Müller, and Stefan Knapp. Development and characterization of type i, type ii, and type iii lim-kinase chemical probes. Journal of Medicinal Chemistry, 65:13264-13287, Sep 2022. URL: https://doi.org/10.1021/acs.jmedchem.2c01106, doi:10.1021/acs.jmedchem.2c01106. This article has 16 citations and is from a highest quality peer-reviewed journal.
12. (hanke2022developmentandcharacterization pages 30-31): Thomas Hanke, Sebastian Mathea, Julia Woortman, Eidarus Salah, Benedict-Tilman Berger, Anthony Tumber, Risa Kashima, Akiko Hata, Bernhard Kuster, Susanne Müller, and Stefan Knapp. Development and characterization of type i, type ii, and type iii lim-kinase chemical probes. Journal of Medicinal Chemistry, 65:13264-13287, Sep 2022. URL: https://doi.org/10.1021/acs.jmedchem.2c01106, doi:10.1021/acs.jmedchem.2c01106. This article has 16 citations and is from a highest quality peer-reviewed journal.
13. (johnson2023anatlasof pages 1-2): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
14. (johnson2023anatlasof pages 3-4): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
15. (johnson2023anatlasof pages 4-5): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
16. (johnson2023anatlasof pages 7-7): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
17. (johnson2023anatlasof pages 9-10): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
18. (kınalı2019leveragingthehuman pages 14-18): M Kınalı. Leveraging the human kinome for anticancer agent cytotoxicity potency prediction. Unknown journal, 2019.
19. (li2025designoptimizationand pages 17-19): Guojun Li, Jionghuang Chen, Rui Chen, and Weihua Yu. Design, optimization, and admet evaluation of s11a-0000168202: a promising limk1 inhibitor for gastric cancer treatment. PLOS One, 20:e0323699, May 2025. URL: https://doi.org/10.1371/journal.pone.0323699, doi:10.1371/journal.pone.0323699. This article has 0 citations and is from a peer-reviewed journal.
20. (mandel2025covalenttargetingleads pages 12-16): Sebastian Mandel, Thomas Hanke, Niall Prendiville, María Baena-Nuevo, Lena Berger, Frederic Farges, Martin-Peter Schwalm, Benedict-Tilmann Berger, Andreas Kraemer, Lewis Elson, Hayuningbudi Saraswati, Kamal Rayees Abdul Azeez, Verena Dederer, Sebastian Mathea, Ana Corrionero, Patricia Alfonso, Sabrina Keller, Matthias Gstaiger, Daniela S. Krause, Susanne Müller, Sandra Röhm, and Stefan Knapp. Covalent targeting leads to the development of limk1 isoform-selective inhibitors. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.17.649341, doi:10.1101/2025.04.17.649341. This article has 0 citations.
21. (mandel2025covalenttargetingleads pages 59-63): Sebastian Mandel, Thomas Hanke, Niall Prendiville, María Baena-Nuevo, Lena Berger, Frederic Farges, Martin-Peter Schwalm, Benedict-Tilmann Berger, Andreas Kraemer, Lewis Elson, Hayuningbudi Saraswati, Kamal Rayees Abdul Azeez, Verena Dederer, Sebastian Mathea, Ana Corrionero, Patricia Alfonso, Sabrina Keller, Matthias Gstaiger, Daniela S. Krause, Susanne Müller, Sandra Röhm, and Stefan Knapp. Covalent targeting leads to the development of limk1 isoform-selective inhibitors. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.17.649341, doi:10.1101/2025.04.17.649341. This article has 0 citations.
22. (mandel2025covalenttargetingleads pages 63-66): Sebastian Mandel, Thomas Hanke, Niall Prendiville, María Baena-Nuevo, Lena Berger, Frederic Farges, Martin-Peter Schwalm, Benedict-Tilmann Berger, Andreas Kraemer, Lewis Elson, Hayuningbudi Saraswati, Kamal Rayees Abdul Azeez, Verena Dederer, Sebastian Mathea, Ana Corrionero, Patricia Alfonso, Sabrina Keller, Matthias Gstaiger, Daniela S. Krause, Susanne Müller, Sandra Röhm, and Stefan Knapp. Covalent targeting leads to the development of limk1 isoform-selective inhibitors. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.17.649341, doi:10.1101/2025.04.17.649341. This article has 0 citations.
23. (mandel2025repurposingofthe pages 11-12): Sebastian Mandel, Thomas Hanke, Sebastian Mathea, Deep Chatterjee, Hayuningbudi Saraswati, Benedict-Tilman Berger, Martin Peter Schwalm, Satoshi Yamamoto, Michiko Tawada, Terufumi Takagi, Mahmood Ahmed, Sandra Röhm, Ana Corrionero, Patricia Alfonso, Maria Baena, Lewis Elson, Amelie Menge, Andreas Krämer, Raquel Pereira, Susanne Müller, Daniela S. Krause, and Stefan Knapp. Repurposing of the ripk1-selective benzo[1,4]oxazepin-4-one scaffold for the development of a type iii limk1/2 inhibitor. ACS Chemical Biology, Apr 2025. URL: https://doi.org/10.1021/acschembio.5c00097, doi:10.1021/acschembio.5c00097. This article has 0 citations and is from a domain leading peer-reviewed journal.
24. (miller2018hominginmechanisms pages 18-22): Chad J. Miller and Benjamin E. Turk. Homing in: mechanisms of substrate targeting by protein kinases. Trends in Biochemical Sciences, 43:380-394, May 2018. URL: https://doi.org/10.1016/j.tibs.2018.02.009, doi:10.1016/j.tibs.2018.02.009. This article has 206 citations and is from a domain leading peer-reviewed journal.
25. (mittelstaedt2012structuralandfunctional pages 23-32): KYMK Mittelstaedt. Structural and functional characterisation of lim kinases. Unknown journal, 2012.
26. (mittelstaedt2012structuralandfunctional pages 38-46): KYMK Mittelstaedt. Structural and functional characterisation of lim kinases. Unknown journal, 2012.
27. (pei2023computationalanalysisof pages 1-2): Jimin Pei and Qian Cong. Computational analysis of regulatory regions in human protein kinases. Protein Science, Sep 2023. URL: https://doi.org/10.1002/pro.4764, doi:10.1002/pro.4764. This article has 3 citations and is from a peer-reviewed journal.
28. (reys2022insilicoprofiling pages 32-35): V Reys. In silico profiling of protein-kinases inhibitors and study of protein-protein interactions. Unknown journal, 2022.
29. (ribba2022theroleof pages 12-13): Anne-Sophie Ribba, Sandrine Fraboulet, Karin Sadoul, and Laurence Lafanechère. The role of lim kinases during development: a lens to get a glimpse of their implication in pathologies. Cells, 11:403, Jan 2022. URL: https://doi.org/10.3390/cells11030403, doi:10.3390/cells11030403. This article has 14 citations and is from a peer-reviewed journal.
30. (salah2019lessonsfromlimk1 pages 12-13): Eidarus Salah, Deep Chatterjee, Alessandra Beltrami, Anthony Tumber, Franziska Preuss, Peter Canning, Apirat Chaikuad, Petra Knaus, Stefan Knapp, Alex N. Bullock, and Sebastian Mathea. Lessons from limk1 enzymology and their impact on inhibitor design. Biochemical Journal, 476:3197-3209, Nov 2019. URL: https://doi.org/10.1042/bcj20190517, doi:10.1042/bcj20190517. This article has 25 citations and is from a domain leading peer-reviewed journal.
31. (salah2019lessonsfromlimk1 pages 13-13): Eidarus Salah, Deep Chatterjee, Alessandra Beltrami, Anthony Tumber, Franziska Preuss, Peter Canning, Apirat Chaikuad, Petra Knaus, Stefan Knapp, Alex N. Bullock, and Sebastian Mathea. Lessons from limk1 enzymology and their impact on inhibitor design. Biochemical Journal, 476:3197-3209, Nov 2019. URL: https://doi.org/10.1042/bcj20190517, doi:10.1042/bcj20190517. This article has 25 citations and is from a domain leading peer-reviewed journal.